CBS 2019
CBSMD教育中心
中 文

ASCVD Prevention

Abstract

Recommended Article

How Far We Have Come, How Far We Have Yet to Go in Atherosclerosis Research Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization Association Between Depressive Symptoms and Incident Cardiovascular Diseases Adenosine and adenosine receptor-mediated action in coronary microcirculation MINOCA: a heterogenous group of conditions associated with myocardial damage Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease : A Special Report From the American Heart Association and American College of Cardiology Lipoprotein(a) in Alzheimer, Atherosclerotic, Cerebrovascular, Thrombotic, and Valvular Disease: Mendelian Randomization Investigation Clinical Risk Factors and Atherosclerotic Plaque Extent to Define Risk for Major Events in Patients Without Obstructive Coronary Artery Disease: The Long-Term Coronary Computed Tomography Angiography CONFIRM Registry

Review Article2020 Apr 24;126(9):1107-1111.

JOURNAL:Circ Res. Article Link

How Far We Have Come, How Far We Have Yet to Go in Atherosclerosis Research

P Libby , KE Bornfeldt. Keywords: allergy and immunology; atherosclerosis; CAD; endothelium; thrombosis.

Full Text PDF